From monotherapy to sequential models: An updated scoping review on ibogaine’s role in treatment for psychiatric disorders
Journal of Psychopharmacology May 12, 2026 Pravesh Sharma, Jared Kendrick, Jennifer Schram et al.
BACKGROUND: Preliminary evidence examining ibogaine in neuropsychiatric and substance use disorders is accumulating. As patient interest and off-label use grow, clinicians require an understanding of emerging dosing strategies, investigational protocols, and reported adverse effects to appropriately counsel patients and contextualize potential risks and benefits. METHODS: Databases were...
DOI: 10.1177/02698811261443674 (opens in new tab)
Observational study
Adverse effect
Dosing
Randomized controlled trial
+10